A Closer Look at Inari Medical Inc’s Recent Stock Surge
In recent trading, shares of Inari Medical Inc (Symbol: NARI) have surpassed the average analyst 12-month target price of $65.38, currently trading at $79.45 per share. When a stock hits an analyst’s target price, the analyst often faces two options: either downgrade on valuation or raise the target price. The decision may also hinge on recent business developments that may have contributed to the stock’s rise. If the company’s prospects appear promising, it might be time for a target price increase.
According to Zacks, 13 different analysts contributed to the average target for Inari Medical Inc. However, this average is not uniform; it reflects a range of opinions. For example, while one analyst predicts a target price of $50.00, another sees potential as high as $86.00. Notably, the standard deviation among the targets is $10.243.
The primary reason for considering the average NARI price target is to utilize the “wisdom of crowds,” combining insights from various analysts to form a more rounded perspective than relying on a single expert’s opinion. With NARI’s stock now above the average target price of $65.38/share, investors should reassess the company’s outlook. The key question is whether $65.38 is merely a milestone on the way to an even higher target or if the valuation has become excessive, signaling a chance to sell some shares. Below is a summary of the current analyst ratings for Inari Medical Inc:
| Recent NARI Analyst Ratings Breakdown | ||||
|---|---|---|---|---|
| » | Current | 1 Month Ago | 2 Months Ago | 3 Months Ago |
| Strong buy ratings: | 10 | 9 | 9 | 9 |
| Buy ratings: | 0 | 0 | 1 | 1 |
| Hold ratings: | 5 | 5 | 5 | 5 |
| Sell ratings: | 0 | 0 | 0 | 0 |
| Strong sell ratings: | 0 | 0 | 0 | 0 |
| Average rating: | 1.67 | 1.71 | 1.73 | 1.73 |
The average rating in the table above operates on a scale of 1 to 5, where 1 is a Strong Buy, and 5 is a Strong Sell. This article utilized data provided by Zacks Investment Research via Quandl.com. For more insights, consider checking out the latest Zacks research report on NARI — at no cost to you.
10 ETFs With Most Upside To Analyst Targets »
Also see:
• Stock MACD
• Top Ten Hedge Funds Holding KFRC
• INDB Historical Stock Prices
The views and opinions expressed herein are those of the author and do not necessarily reflect the views of Nasdaq, Inc.
